Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA-dependent aggregation of a common TEV protease variant alters <i>in vitro</i> biomolecular condensate reconstitution.

bioRxiv : the preprint server for biology·2026
Same author

Inherent Specificity and Variation Sensitivity as Quantitative Metrics for RBP Binding.

bioRxiv : the preprint server for biology·2026
Same author

Molecular insights into DDX3X-androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer.

Oncogene·2026
Same author

Marine Pharmacology in 2022-2023: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities, Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action.

Marine drugs·2026
Same author

Phase separation of PGL-3 driven by structured domains that oligomerize and interact with RGG motifs.

EMBO reports·2026
Same author

A cellular basis for the mammalian nocturnal-diurnal switch.

Science (New York, N.Y.)·2026

Related Experiment Video

Updated: Dec 29, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.3K

A comparative study of small molecules targeting eIF4A.

Sai Kiran Naineni1, Rayelle Itoua Maïga1, Regina Cencic1

  • 1Department of Biochemistry, McGill University, Montreal, Québec H3G 1Y6, Canada.

RNA (New York, N.Y.)
|February 5, 2020
PubMed
Summary
This summary is machine-generated.

Researchers compared new small molecules targeting eukaryotic initiation factor 4A (eIF4A) to hippuristanol. This analysis aims to identify novel anticancer drugs by understanding eIF4A inhibition in cancer.

Keywords:
RNA helicaseeIF4AeIF4Fhippuristanoltranslation initiation

More Related Videos

Identification of Protein Interacting Partners Using Tandem Affinity Purification
10:02

Identification of Protein Interacting Partners Using Tandem Affinity Purification

Published on: February 25, 2012

38.1K
Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.0K

Related Experiment Videos

Last Updated: Dec 29, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.3K
Identification of Protein Interacting Partners Using Tandem Affinity Purification
10:02

Identification of Protein Interacting Partners Using Tandem Affinity Purification

Published on: February 25, 2012

38.1K
Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The PI3K/Akt/mTOR pathway is frequently dysregulated in human cancers.
  • The eukaryotic initiation factor 4F (eIF4F) complex, regulated by this pathway, controls translation initiation and is crucial for tumor growth.
  • eIF4F hyperactivity, driven by elevated PI3K/Akt/mTOR signaling, creates vulnerabilities exploitable by targeted therapies.

Purpose of the Study:

  • To comparatively analyze the biological activity and specificity of newly developed small molecules targeting the eIF4A helicase.
  • To evaluate these novel compounds against the established eIF4A inhibitor, hippuristanol, for potential anticancer drug development.

Main Methods:

  • Comparative analysis of small molecule inhibitors.
  • Assessment of biological activity and specificity against eIF4A.
  • Preclinical evaluation in cancer models (in vitro and in vivo).

Main Results:

  • Identification and characterization of novel small molecules targeting eIF4A.
  • Direct comparison of the efficacy and selectivity of these new agents with hippuristanol.
  • Evaluation of their anticancer potential in preclinical settings.

Conclusions:

  • New small molecules targeting eIF4A show promise as anticancer agents.
  • Comparative analysis with hippuristanol provides crucial insights into their therapeutic potential.
  • Further investigation of these eIF4A inhibitors could lead to novel cancer treatments.